EXAGEN INC. Defined Contribution Plan, Cost
EXAGEN INC. (XGN) reported Defined Contribution Plan, Cost of $1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-10
- EXAGEN INC. defined contribution plan, cost for fiscal 2025 was $1.00M, a 25.00% increase from fiscal 2024.
- EXAGEN INC. defined contribution plan, cost for fiscal 2024 was $800.00K, a 0.00% change from fiscal 2023.
- EXAGEN INC. defined contribution plan, cost for fiscal 2023 was $800.00K, a 11.11% decline from fiscal 2022.
- EXAGEN INC. defined contribution plan, cost for fiscal 2022 was $900.00K, a 80.00% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $1.00M 10-K · filed 2026-03-10 |
| 2024-12-31 | $800.00K 10-K · filed 2026-03-10 |
| 2023-12-31 | $800.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $900.00K 10-K · filed 2024-03-18 |
| 2021-12-31 | $500.00K 10-K · filed 2023-03-20 |
| 2020-12-31 | $500.00K 10-K · filed 2022-03-22 |
| 2019-12-31 | $400.00K 10-K · filed 2021-03-16 |
| 2018-12-31 | $400.00K 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |